Bipartisan Senate bill to cap insulin for Americans at $35 has new momentum

A bipartisan group of senators is resurfacing legislation to cap many American patients’ insulin costs at $35 a month — the INSULIN Act of 2026 — reviving a push that previously stalled.

The bill, co-authored by Sens. Jeanne Shaheen, D-N.H., Susan Collins, R-Maine, Raphael Warnock, D-Ga., and John Kennedy, R-La., would bar group and individual health plans from imposing deductibles on selected insulin products and could not charge more than $35 for a 30-day supply starting in plan year 2027.